Yeomans Consulting Group, Inc. Belite Bio, Inc Transaction History
Yeomans Consulting Group, Inc.
- $341 Billion
- Q4 2025
A detailed history of Yeomans Consulting Group, Inc. transactions in Belite Bio, Inc stock. As of the latest transaction made, Yeomans Consulting Group, Inc. holds 2,399 shares of BLTE stock, worth $280,011. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,399Holding current value
$280,011% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding BLTE
# of Institutions
36Shares Held
2.28MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA875KShares$102 Million1.11% of portfolio
-
Rtw Investments, LP New York, NY313KShares$36.5 Million0.31% of portfolio
-
Vestal Point Capital, LP New York, NY313KShares$36.5 Million1.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT210KShares$24.5 Million0.94% of portfolio
-
Eventide Asset Management, LLC Boston, MA195KShares$22.8 Million0.27% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $2.9B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...